ESR2 and ovarian carcinoma: In ovarian cancer, pooled evidence indicates that ERβ’s favorable prognostic association emerges most clearly when ERβ1-specific clones (PPG5/10 or EMR02) are used, and single-cohort studies have linked cytoplasmic ERβ positivity to longer survival, highlighting subcellular localization and reagent effects [30,31].